Effect of intravenous metoprolol on reversible obstructive airways disease
- PMID: 7214788
- DOI: 10.1038/clpt.1981.81
Effect of intravenous metoprolol on reversible obstructive airways disease
Abstract
We gave increasing doses of metoprolol intravenously to seven subjects with stable chronic obstructive pulmonary disease (COPD) who were also receiving their usual bronchodilators. Six of the seven tolerated up to 0.2mg/kg metoprolol without adverse effects, although there were declines in forced expiratory volume in 1 sec (FEV1). At 0.15 mg/kg mean FEV1 fell 12% (p less than 0.025), and at 0.2 mg/kg mean decline in FEV1 was 15% (p less than 0.01). These findings suggest that 0.2 mg/kg metoprolol may be given intravenously to most patients with COPD in addition to previously administered bronchodilators without precipitating clinically significant adverse effects. Any side effects that develop can be reversed by beta agonists.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources